One Capital Management LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,274 shares of the biopharmaceutical company’s stock after purchasing an additional 4,621 shares during the quarter. One Capital Management LLC’s holdings in Gilead Sciences were worth $2,696,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently bought and sold shares of the company. Keel Point LLC increased its holdings in shares of Gilead Sciences by 0.4% in the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares during the period. Paradigm Financial Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 26 shares during the period. West Oak Capital LLC lifted its holdings in shares of Gilead Sciences by 0.7% in the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 32 shares during the period. First Heartland Consultants Inc. raised its holdings in Gilead Sciences by 0.4% in the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after purchasing an additional 39 shares during the period. Finally, Princeton Portfolio Strategies Group LLC raised its holdings in Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after purchasing an additional 41 shares during the period. 75.94% of the stock is currently owned by institutional investors.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down $0.04 on Friday, reaching $79.02. 6,342,448 shares of the company’s stock traded hands, compared to its average volume of 8,150,000. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The firm has a market cap of $103,190.00, a PE ratio of 8.99, a PEG ratio of -1.68 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter last year, the firm earned $2.75 EPS. Gilead Sciences’s quarterly revenue was down 13.2% compared to the same quarter last year. sell-side analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.66%.
In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares in the company, valued at $224,302,912.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. In the last three months, insiders sold 461,666 shares of company stock worth $34,072,567. 1.30% of the stock is currently owned by insiders.
A number of research firms have commented on GILD. Morgan Stanley restated an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Bank of America cut their price objective on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research report on Wednesday, October 4th. Jefferies Group reaffirmed a “hold” rating and issued a $93.00 target price on shares of Gilead Sciences in a research note on Wednesday, October 4th. Barclays reissued an “overweight” rating and set a $90.00 price objective on shares of Gilead Sciences in a research note on Wednesday, October 11th. Finally, Leerink Swann lifted their target price on shares of Gilead Sciences from $87.00 to $89.00 and gave the company a “market perform” rating in a report on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $85.03.
TRADEMARK VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/gilead-sciences-inc-gild-holdings-boosted-by-one-capital-management-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.